| 0.4059 -0.008 (-1.93%) | 07-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.55 | 1-year : | 0.64 |
| Resists | First : | 0.47 | Second : | 0.55 |
| Pivot price | 0.41  |
|||
| Supports | First : | 0.36 | Second : | 0.3 |
| MAs | MA(5) : | 0.4  |
MA(20) : | 0.42 |
| MA(100) : | 0.78 |
MA(250) : | 1.94 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 43.7 |
D(3) : | 40.3 |
| RSI | RSI(14): 39.1 |
|||
| 52-week | High : | 5.69 | Low : | 0.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VVOS ] has closed above bottom band by 37.6%. Bollinger Bands are 87.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.43 - 0.43 | 0.43 - 0.43 |
| Low: | 0.4 - 0.4 | 0.4 - 0.4 |
| Close: | 0.4 - 0.41 | 0.41 - 0.41 |
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Thu, 30 Jul 2026
Vivos Therapeutics Inc (VVOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Tue, 28 Jul 2026
Vivos Therapeutics Inc (VVOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Sat, 25 Jul 2026
Vivos Therapeutics, Inc. Revenue Breakdown – NASDAQ:VVOS - TradingView
Fri, 24 Jul 2026
VVOS|Vivos Therapeutics Inc|Price:0.395|Chg%:+0.002 - tradingkey.com
Thu, 09 Jul 2026
Price to earnings forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView
Mon, 22 Jun 2026
Vivos gets more time to convert $4.5M debt into equity - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 1.213e+007 (%) |
| Held by Institutions | 26.3 (%) |
| Shares Short | 947 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.1e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -127.7 % |
| Operating Margin | -128.7 % |
| Return on Assets (ttm) | -77.8 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 1.957e+007 % |
| Gross Profit (p.s.) | 11.51 |
| Sales Per Share | 98 |
| EBITDA (p.s.) | 1.97549e+006 |
| Qtrly Earnings Growth | -2.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 8.01 |
| Dividend | 0 |
| Forward Dividend | 1.2e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|